On March 19, 2018, the research team of the Laboratory led by Li Jing took the initiative to carry out the first case of targeted therapy for asthma with Xolair (Omalizumab monoclonal anti-body) nationwide, which was used to treat the patients of moderate to severe allergic asthma aged above 12 years old whose treatment and control effect is not good by inhaling hormone combination long-acting β2- adrenergic agonist. It was reported that its emergency has provided a new and effective treatment option for the patients of moderate to severe allergic asthma with a poor control effect under the current diagnosis and treatment schemes of China, which also signified that China has entered a new era of precision therapy of respiratory disease.

With the promotion and popularization of the concept and model of targeted treatment for asthma, in the near future patients will be able to receive one-stop diagnosis and treatment services including pre-diagnosis evaluation, allergen detection, diagnosis, targeted therapy, health education and follow-up visit.